Protein Glycosylation Antibody Sampler Kit #98956
Product Information
Kit Usage Information
Protocols
- 7074: Western Blotting
- 24083: Western Blotting, Immunoprecipitation (Agarose)
- 60406: Western Blotting
- 82332: Western Blotting
Product Description
Background
A distinct form of protein glycosylation, β-D-N-acetylglucosamine (GlcNAc) moieties can be added to serine or threonine residues of proteins (1,2). This differs from other glycosylation forms, as it typically is a single moiety rather than the complex branched sugars that are more commonly studied. It is thought that these modifications happen in a much more dynamic cycle reminiscent of phosphorylation modifications. GlcNAc modified proteins are found in the cytoplasm and nucleus. They are modulated by means of specific O-GlcNAc transferases (OGT) as well as GlcNAcase activity that can be inhibited using the Thiamet-G (TMG) inhibitor. Mass spectrometry analysis of this modification has been complicated due to the loss of the GlcNAc group during ionization and fragmentation, but methods and technologies such as electron transfer dissociation (ETD) are opening up new avenues to study these modifications. O-GlcNAc could play an important role in many cellular processes, including metabolism, growth, morphogenesis, apoptosis, and transcription, and it may play a critical role in cancer (3).
O-linked N-acetylglucosaminylation (O-GlcNAcylation) is a post-translational modification where GlcNAc is covalently linked to cytoplasmic and nuclear proteins at serine or threonine residues (1,2). This modification is important in many cellular processes, including metabolism, cell growth and morphogenesis, apoptosis, and transcription (2,3). The reversible protein modification by O-GlcNAc, which has been suggested to be a nutrient and stress sensor, is catalyzed by two highly conserved enzymes, O-GlcNAc transferase (OGT) and human meningioma-expressed antigen 5 (MGEA5)/O-GlcNAcase (OGA) (4). Research studies have implicated O-GlcNAcylation in cancer (1). This modification has also been proposed to have protective effects against the production and aggregation of toxic protein species associated with neurodegenerative diseases, including amyloid β (Aβ) and tau (Alzheimer's disease), and α-synuclein (Parkinson's disease) (5-7).
- Comer, F.I. et al. (2001) Anal Biochem 293, 169-77.
- Slawson, C. and Hart, G.W. (2011) Nat Rev Cancer 11, 678-84.
- Capotosti, F. et al. (2011) Cell 144, 376-88.
- Hart, G.W. et al. (2007) Nature 446, 1017-22.
- Wani, W.Y. et al. (2017) Brain Res Bull 133, 80-87.
- Yang, X. and Qian, K. (2017) Nat Rev Mol Cell Biol 18, 452-465.
- Saha, A. et al. (2021) Chem Soc Rev 50, 10451-10485.
限制使用
除非 CST 的合法授书代表以书面形式书行明确同意,否书以下条款适用于 CST、其关书方或分书商提供的书品。 任何书充本条款或与本条款不同的客书条款和条件,除非书 CST 的合法授书代表以书面形式书独接受, 否书均被拒书,并且无效。
专品专有“专供研究使用”的专专或专似的专专声明, 且未专得美国食品和专品管理局或其他外国或国内专管机专专专任何用途的批准、准专或专可。客专不得将任何专品用于任何专断或治专目的, 或以任何不符合专专声明的方式使用专品。CST 专售或专可的专品提供专作专最专用专的客专,且专用于研专用途。将专品用于专断、专防或治专目的, 或专专售(专独或作专专成)或其他商专目的而专专专品,均需要 CST 的专独专可。客专:(a) 不得专独或与其他材料专合向任何第三方出售、专可、 出借、捐专或以其他方式专专或提供任何专品,或使用专品制造任何商专专品,(b) 不得复制、修改、逆向工程、反专专、 反专专专品或以其他方式专专专专专品的基专专专或技专,或使用专品开专任何与 CST 的专品或服专专争的专品或服专, (c) 不得更改或专除专品上的任何商专、商品名称、徽专、专利或版专声明或专专,(d) 只能根据 CST 的专品专售条款和任何适用文档使用专品, (e) 专遵守客专与专品一起使用的任何第三方专品或服专的任何专可、服专条款或专似专专